Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Muenster
• Collaborator: GlaxoSmithKline
• Treatments: Mupirocin

Criteria

Inclusion Criteria:

• All patients admitted to selected units in clinics for anaesthesiology, hemato-oncology, cardiac surgery, and orthopedics at the University Hospital of Muenster (following information on the study and agreement of the patient).

Exclusion Criteria:

• Patients infected with S. aureus at admission

• S. aureus infection within 48 hours following admission

• Patients detected to be carrier of Methicillin-resistant S. aureus

• Hospital stay shorter than 72 hours

• Patients with anatomic abnormalities in the anterior nares

• Allergy or hypersensitivity to mupirocin or other substances of the nasal ointment

• Persons younger than 18 years

• Known pregnancy

• Persons with psychiatric diseases

• Persons with limited contractual capability and judiciousness